Lincoln National Corp’s BlackRock Health Sciences Trust BME Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
– Sell
-4,316
Closed -$209K – 918
2021
Q4
$209K Buy
4,316
+57
+1% +$2.7K ﹤0.01% 835
2021
Q3
$203K Buy
4,259
+53
+1% +$2.58K ﹤0.01% 816
2021
Q2
$204K Buy
+4,206
New +$201K ﹤0.01% 809
2020
Q3
– Sell
-5,458
Closed -$223K – 686
2020
Q2
$223K Buy
+5,458
New +$220K 0.01% 573
2020
Q1
– Sell
-5,296
Closed -$225K – 595
2019
Q4
$225K Buy
5,296
+78
+1% +$3.09K 0.01% 578
2019
Q3
$200K Buy
5,218
+80
+2% +$3.08K 0.01% 543
2019
Q2
$200K Buy
5,138
+82
+2% +$3.12K 0.01% 528
2019
Q1
$201K Buy
+5,056
New +$200K 0.01% 484

Other funds holding BME

Lincoln National Corp's BME Position: Q1 2022 in Review

Lincoln National Corp sold out of BlackRock Health Sciences Trust (BME) in Q1 2022, closing a stake of 4,316 shares — an estimated $209K sold.

Lincoln National Corp first reported a position in BME in Q1 2019 and held it in 8 quarters. The position peaked at $225K in Q4 2019. 58 funds tracked by Wall St. Rank hold BME as of Q1 2022.

  • Lincoln National Corp reported no remaining BlackRock Health Sciences Trust position as of Q1 2022 after selling out during the quarter.
  • Lincoln National Corp sold 4,316 BlackRock Health Sciences Trust shares in Q1 2022, an estimated $209K.
  • Lincoln National Corp first reported a position in BlackRock Health Sciences Trust in Q1 2019 and held it in 8 quarters.
  • Lincoln National Corp's BlackRock Health Sciences Trust position peaked at $225K in Q4 2019.
  • 58 funds tracked by Wall St. Rank held BlackRock Health Sciences Trust as of Q1 2022.

Based on Lincoln National Corp's 13F filing for Q1 2022, filed 9 May 2022.